Sen. Richard J. Durbin

Maddy summarySenate Bill 1466, the Resources for Victims of Gun Violence Act of 2025, establishes an Advisory Council to help victims of gun violence access available resources. The Council, composed of federal agency heads and appointed victims/victim professionals, will identify best practices and create a public resource guide covering medical, financial, mental health, legal, and housing needs. It must produce an initial report within 180 days of enactment (and a follow-up report after two years), sharing this information with Congress, state agencies, and the public through online and print materials. The bill does not authorize new funding and expires after five years.

Protecting Children with Food Allergies Act of 2025 This bill requires that local school food service personnel receive annual training and certification on food allergies as part of the training provided by the National School Lunch Program of the Department of Agriculture. Under current law, the mandatory training and certification for school food service personnel must include modules on (1) nutrition, and (2) health and food safety standards and methodologies. Under the bill, the training and certification must also include a module on food allergies, including information on the best practices to prevent, recognize, and respond to food-related allergic reactions. As part of the certification, the bill also requires that food service personnel demonstrate competence in the training provided.

Maddy summaryThis bill prohibits "reverse payment" agreements where brand-name drug companies pay generic or biosimilar manufacturers to delay entering the market, which harms competition. It creates a presumption that such agreements are anticompetitive if a generic or biosimilar company receives value in exchange for delaying market entry, with exceptions for standard settlements involving early market entry rights or reasonable litigation expenses. The bill amends the Federal Trade Commission Act to enforce this new prohibition and requires certification of such agreements, aiming to enhance competition and lower drug costs for consumers. This would directly affect brand-name drug companies, generic manufacturers, and biosimilar biological product manufacturers.

Maddy summaryThe Stop STALLING Act empowers the Federal Trade Commission (FTC) to take action against pharmaceutical companies that submit "sham" petitions under drug approval processes. Specifically, it targets petitions that are objectively baseless and used to delay generic drug approvals, directly affecting drug manufacturers filing such petitions. The bill establishes civil penalties of up to $50,000 per day or the revenue earned from the delayed drug during the petition's review period. It creates a presumption of "sham" status if the Health Secretary determines a petition was filed primarily to delay approval, with companies able to rebut this presumption. The law does not alter FDA drug approval rules but adds FTC enforcement for unfair competition tactics.

Maddy summaryThe provided context does not include a substantive summary or bill text beyond the short title. Without details on the bill's specific provisions, mechanisms, or affected parties, a factual summary cannot be generated. The title "Interagency Patent Coordination and Improvement Act of 2025" suggests a focus on federal patent processes, but no concrete policy changes are described in the given text. For an accurate summary, the full bill language or official summary would be required.

Maddy summaryThe Drug Competition Enhancement Act (S.1040) prohibits drug manufacturers from engaging in "product hopping" - a practice where companies withdraw or disadvantage their original drug to push a newer "follow-on" version when generic or biosimilar competitors are about to enter the market. Specifically, it bans "hard switches" (officially withdrawing the original drug or destroying inventory to block generics) and "soft switches" (unfairly disadvantaging the original drug to favor the follow-on product) during a 3-year window before generic competition begins. The Federal Trade Commission (FTC) can enforce this by taking legal action against violators, seeking injunctions, or requiring disgorgement of profits gained from anti-competitive conduct. This law directly affects drug manufacturers holding approved "reference products" when generic or biosimilar applications are pending, aiming to prevent artificial barriers to lower-cost alternatives.

Maddy summaryThis resolution (SRES 168) expresses the U.S. Senate's support for the "Rise Up for LGBTQI+ Youth in Schools Initiative," which calls on communities to demand equal educational opportunities, civil rights protections, and inclusion for LGBTQI+ students in K-12 schools. It specifically highlights the need to address anti-LGBTQI+ policies in states - including restrictions on sports participation, bathroom access, and classroom curricula - and cites research showing these policies harm students' mental health, academic performance, and sense of safety. The resolution urges states and localities to adopt inclusive policies like anti-bullying protections and gender-neutral dress codes to create affirming school environments. It does not create new laws but serves as a symbolic endorsement of efforts to combat discrimination against LGBTQI+ youth, particularly transgender, nonbinary, and students of color.

Maddy summaryThe NO FAKES Act of 2025 establishes legal rights for individuals to control how their voice and visual likeness is used in AI-generated digital replicas. It defines "digital replicas" as highly realistic computer-generated representations that are readily identifiable as an individual's voice or appearance, granting individuals (and their heirs) the right to authorize or prohibit such uses. The law creates liability for unauthorized use of digital replicas or distribution of products designed to create them without authorization, while providing safe harbors for online services that follow specific procedures for handling claims. It preempts state laws regarding voice and visual likeness rights in digital replicas (with limited exceptions) and establishes a 10-year post-mortem right that can be renewed for additional 5-year periods if there's active public use.

Maddy summaryThe GOSAFE Act prohibits the import, sale, manufacture, transfer, or possession of gas-operated semi-automatic firearms and large capacity ammunition feeding devices (those holding more than 10 rounds). It defines gas-operated firearms as those using gas pressure to cycle the action and requires the Attorney General to publish a list of prohibited firearms within 180 days. The bill includes exemptions for single-shot weapons, muzzle-loaders, firearms with permanently fixed magazines under 10 rounds, and certain other specific types. Manufacturers must now seek approval for new semi-automatic firearms through a process requiring detailed documentation, and the bill establishes a Firearm Safety Trust Fund to cover administrative costs. Violations of these provisions can result in fines up to $5,000 or up to 12 months in prison.

Maddy summaryThe BUMP Act (S 1374) bans devices that increase the firing rate of semiautomatic firearms to mimic machineguns, directly affecting owners of modified firearms. It prohibits importing, selling, or possessing devices (like "bump stocks") that speed up firing or eliminate the need for separate trigger pulls, and requires registration of existing modified semiautomatics within 120 days. The law exempts government agencies and pre-enactment modifications that are registered. This targets specific firearm modifications, not all semiautomatic weapons.